Building a Quality System That Survives Due Diligence

Private equity firms and strategic acquirers have gotten significantly smarter about quality system risk in MedTech over the past five years. It used to be enough to confirm that a target company had an ISO 13485 certificate on the wall and no outstanding warning letters. That's no longer the bar. Today's diligence teams — the good ones, at least — dig into the quality system with the same rigor they apply to financials, IP portfolios, and revenue recognition.

And what they find frequently changes the terms of the deal.

Quality Findings Hit the Deal Table

Quality system deficiencies discovered during diligence don't just raise compliance concerns. They translate directly into financial consequences: purchase price adjustments, escrow holdbacks to cover remediation costs, earn-out structures that tie payouts to quality milestones, or in the worst cases, deals that fall apart entirely.

I've watched acquisition teams reduce offers by millions based on what they found in a company's CAPA backlog. I've seen escrow holdbacks structured around the estimated cost of remediating design history file deficiencies. The quality system is no longer a back-office compliance function that gets a passing glance during diligence. It's a material factor in enterprise valuation.

Your quality system is a financial asset. If it can't withstand structured diligence, it will cost you at the deal table — in real dollars, not hypothetical risk.

What Acquirers Actually Look For

Sophisticated diligence teams have a well-defined playbook for quality system evaluation. They're looking at specific indicators that reveal the true health of the operation — not just the surface-level documentation.

Each of these areas tells a story. Individually, a single weakness might be manageable. But when diligence reveals a pattern — open CAPAs that have been lingering for two years, complaint trends that management reviews never address, a 483 history with repeat observations — the story becomes one of systemic risk. And systemic risk gets priced into the deal.

The Timeline Problem

Here's the practical challenge that makes quality diligence particularly difficult: traditional quality system audits take four to six weeks. Deal teams operate on compressed timelines measured in days. The information asymmetry is enormous — acquirers need to evaluate the quality system fast enough to inform deal terms, but the traditional approach to quality assessment doesn't support that pace.

This creates a dangerous dynamic. Either the quality review is rushed and superficial — meaning real risks go undetected until after close — or the deal timeline stretches to accommodate a proper review, which introduces its own risks in a competitive process.

Common Surprises That Kill Deal Value

In my experience leading quality diligence engagements, certain surprises show up with uncomfortable regularity.

• Undisclosed 483 observations. Not every company is forthcoming about its FDA history. Sometimes it's deliberate; sometimes the institutional memory has simply been lost through leadership turnover. Either way, discovering unreported observations during diligence is a trust-destroying event.
• Supplier audit gaps. Companies that rely on critical suppliers but haven't conducted supplier audits in years — or have no documented supplier qualification process at all. Under QMSR, supplier controls are a core requirement. Gaps here represent both compliance risk and operational risk.
• Design history files that don't hold up. Design controls are often the weakest area of the quality system, particularly for companies that developed their flagship products before implementing a mature QMS. Incomplete risk management files, missing design verification records, and traceability gaps between user needs and design outputs are perennial findings.
• CAPA backlogs. A CAPA system where the oldest open items are measured in years rather than months signals an organization that identifies problems but lacks the discipline or resources to resolve them. This is a remediation cost that acquirers will estimate and deduct.

What Quality Leaders Can Do Now

The smartest thing a quality leader can do is prepare for diligence before anyone's looking. Whether your company is actively exploring a transaction or simply wants to operate at a level that would withstand external scrutiny, the actions are the same.

• Run a comprehensive internal audit. Not a sampling-based review — a thorough assessment that covers every QMS process with full document coverage. Identify what an external reviewer would find before they find it.
• Close open CAPAs. Prioritize the oldest and most severe. Verify effectiveness with documented evidence. A clean CAPA register demonstrates operational discipline.
• Clean up design history files. Ensure traceability from user needs through design inputs, outputs, verification, and validation. Fill documentation gaps. Make the risk management file complete and current.
• Ensure management reviews reflect real performance. Data-driven inputs, documented decisions, assigned action items with follow-through. Management reviews should tell the story of an organization that's actively managing quality — not just checking a regulatory box.
• Document process interactions. Under QMSR and ISO 13485, the relationship between QMS processes matters. Can you demonstrate how design controls feed into production controls, how complaint data informs risk management, how supplier performance is monitored and acted upon?

How MB&A Delivers Quality Due Diligence

This is exactly the problem MB&A was built to solve. Traditional quality diligence is too slow for deal timelines and too shallow to catch systemic risk. We operate differently.

Using Qualera's AI-native audit intelligence, MB&A conducts quality due diligence at the speed deal teams require. The platform analyzes the full quality system documentation — every SOP, every record, every process interaction — and produces a structured output: a quality risk report, finding severity matrix, and regulatory exposure summary. Not in four to six weeks. In days.

We deliver the quality risk picture that deal teams need — with the depth that traditional diligence timelines can't provide and the speed that competitive transactions demand.

Human auditors remain in command of every judgment. Qualera provides the comprehensive evidence base; our team interprets findings, assesses materiality, and delivers actionable intelligence to the deal team. The result is a diligence product that PE firms and strategic acquirers can actually use to make informed decisions — on their timeline, not ours.

The Bottom Line

Your quality system is a financial asset. It affects your company's valuation, your negotiating position, and the terms under which any transaction closes. Companies that treat the quality system as a compliance cost center are consistently surprised when it becomes a line item in deal negotiations.

Companies that treat it as the strategic asset it is — maintaining it, investing in it, ensuring it can withstand external scrutiny — enter diligence from a position of strength. The quality system doesn't become a liability to be negotiated around. It becomes evidence of operational maturity that supports enterprise value.

The acquirers are getting smarter. Make sure your quality system is ready for the conversation.